Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
-
Ad hoc release
Novartis delivered sales growth and core margin expansion in Q3; raised FY core operating income guidance
Ad hoc announcement pursuant to Art. 53 LRThird quarterQ3 net sales grew +4% (cc¹, +4% USD), with core operating income¹ +10% (cc, +11% USD)Sales growth driven by priority brands including Kisqali (+… -
Ad hoc release
Novartis verzeichnete im dritten Quartal Steigerungen der Umsätze und der Kerngewinnmarge; Prognose für das operative Kernergebnis im Geschäftsjahr erhöht
Ad-hoc-Mitteilung gemäss Art. 53 KRDrittes QuartalDer Nettoumsatz stieg im dritten Quartal um +4% (kWk¹, +4% USD), das operative Kernergebnis¹ verbesserte sich um +10% (kWk, +11% USD)Das… -
Press release
Novartis remibrutinib delivered comprehensive disease control in Phase III RMS trials, with proven, robust safety profile
Remibrutinib achieved significant and clinically meaningful reduction in relapses vs. teriflunomide, to approximately 1 relapse every 13 years, without the need for chronic B-cell depletion¹˒²MRI… -
Press release
Kisqali® shows clinically meaningful overall survival in broadest HR+/HER2- early breast cancer population at high risk of recurrence
Six-year NATALEE analysis showed ~20% reduction in risk of death compared to ET alone1 Benefit increased over time in invasive disease-free survival and across key secondary endpoints1-3 Patients off… -
Press release
Novartis receives European Commission approval for Cosentyx® in polymyalgia rheumatica (PMR)
Cosentyx® (secukinumab) becomes first and only IL-17A inhibitor approved in Europe for adults with PMR,1 a common inflammatory rheumatic disease with limited advanced treatment options2-6Approval… -
Story People and Culture
Novartis ranks #19 in TIME and Statista’s World’s Best Companies 2026
Novartis has earned a spot among the world’s top performers, ranking #19 in TIME and Statista’s World’s Best Companies 2026 – a significant rise from #114 last year. The recognition reflects progress across three critical areas: business performance, workplace experience, and sustainability.
-
Story Access to Healthcare
Community health takes a village: Screening in the barber’s chair
Novartis is working with community partners to bring heart disease and cancer screening, information and support closer to where people are.
-
Story People and Culture
Novartis achieves Tier 1 in the 2026 CCLA Corporate Mental Health Benchmark
Novartis has reached the highest performance tier in the CCLA Corporate Mental Health Benchmark, recognizing a comprehensive approach to workplace mental health, wellbeing and employee support.
-
Press release
Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)
In Phase III RemIND trial, twice as many adults taking Rhapsido achieved complete hive resolution by Week 12 vs placebo, with responses seen by Week 21SD is most prevalent type of chronic inducible… -
Press release
Novartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026
Late-breaking data from positive Phase III REMODEL-1/-2 trials will show efficacy and safety profile of remibrutinib in RMS Novartis to hold virtual investor event highlighting REMODEL data and… -
Story People and Culture
The patient who changed the course of my career
Nazem Atassi, Development Unit Head for Neuroscience and Gene Therapies, Global Drug Development.
-
Story Access to Healthcare
Community health takes a village: from Pulpit to Pew
Millions of people around the world continue to face barriers to prevention, diagnosis and treatment for chronic diseases such as heart disease and cancer. To help address these gaps, Novartis is scaling its community health programs from 11 to more than 30 countries by 2030, working alongside local partners to connect more people to care.
-
Ad hoc release
Novartis delivered sales growth and core margin expansion in Q3; raised FY core operating income guidance
Ad hoc announcement pursuant to Art. 53 LRThird quarterQ3 net sales grew +4% (cc¹, +4% USD), with core operating income¹ +10% (cc, +11% USD)Sales growth driven by priority brands including Kisqali (+… -
Ad hoc release
Novartis verzeichnete im dritten Quartal Steigerungen der Umsätze und der Kerngewinnmarge; Prognose für das operative Kernergebnis im Geschäftsjahr erhöht
Ad-hoc-Mitteilung gemäss Art. 53 KRDrittes QuartalDer Nettoumsatz stieg im dritten Quartal um +4% (kWk¹, +4% USD), das operative Kernergebnis¹ verbesserte sich um +10% (kWk, +11% USD)Das… -
Press release
Novartis remibrutinib delivered comprehensive disease control in Phase III RMS trials, with proven, robust safety profile
Remibrutinib achieved significant and clinically meaningful reduction in relapses vs. teriflunomide, to approximately 1 relapse every 13 years, without the need for chronic B-cell depletion¹˒²MRI… -
Press release
Kisqali® shows clinically meaningful overall survival in broadest HR+/HER2- early breast cancer population at high risk of recurrence
Six-year NATALEE analysis showed ~20% reduction in risk of death compared to ET alone1 Benefit increased over time in invasive disease-free survival and across key secondary endpoints1-3 Patients off… -
Press release
Novartis receives European Commission approval for Cosentyx® in polymyalgia rheumatica (PMR)
Cosentyx® (secukinumab) becomes first and only IL-17A inhibitor approved in Europe for adults with PMR,1 a common inflammatory rheumatic disease with limited advanced treatment options2-6Approval… -
Press release
Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)
In Phase III RemIND trial, twice as many adults taking Rhapsido achieved complete hive resolution by Week 12 vs placebo, with responses seen by Week 21SD is most prevalent type of chronic inducible… -
Press release
Novartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026
Late-breaking data from positive Phase III REMODEL-1/-2 trials will show efficacy and safety profile of remibrutinib in RMS Novartis to hold virtual investor event highlighting REMODEL data and… -
Press release
Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)
If approved, Cosentyx (secukinumab) will be first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica (PMR), providing new treatment option after steroids¹Recommendation based… -
Ad hoc release
Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)
Ad hoc announcement pursuant to Art. 53 LR HARBOR did not meet its primary endpoint of vHOT in DM1, a progressive neuromuscular disease with high unmet need and no approved treatment options Del-… -
Ad hoc release
Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
Ad hoc announcement pursuant to Art. 53 LR Basel, September 4, 2026 – Novartis today announced that the pelacarsen phase III Lp(a)HORIZON trial, a pioneering cardiovascular outcomes study, did not… -
Ad hoc release
Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials
Ad hoc announcement pursuant to Art. 53 LR REMODEL-1/-2 trials met their primary endpoint, significantly reducing annualized relapse rate (ARR) vs teriflunomide in people living with… -
Press release
Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies
Late-breaking Phase IV VICTORION-CHALLENGE data will evaluate Leqvio® (inclisiran) vs. bempedoic acid in achieving LDL-C goalsNew AZALEA-TIMI 71 analyses will further characterize the bleeding…
-
Ad hoc release
Novartis delivered sales growth and core margin expansion in Q3; raised FY core operating income guidance
Ad hoc announcement pursuant to Art. 53 LRThird quarterQ3 net sales grew +4% (cc¹, +4% USD), with core operating income¹ +10% (cc, +11% USD)Sales growth driven by priority brands including Kisqali (+… -
Ad hoc release
Novartis verzeichnete im dritten Quartal Steigerungen der Umsätze und der Kerngewinnmarge; Prognose für das operative Kernergebnis im Geschäftsjahr erhöht
Ad-hoc-Mitteilung gemäss Art. 53 KRDrittes QuartalDer Nettoumsatz stieg im dritten Quartal um +4% (kWk¹, +4% USD), das operative Kernergebnis¹ verbesserte sich um +10% (kWk, +11% USD)Das… -
Ad hoc release
Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)
Ad hoc announcement pursuant to Art. 53 LR HARBOR did not meet its primary endpoint of vHOT in DM1, a progressive neuromuscular disease with high unmet need and no approved treatment options Del-… -
Ad hoc release
Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
Ad hoc announcement pursuant to Art. 53 LR Basel, September 4, 2026 – Novartis today announced that the pelacarsen phase III Lp(a)HORIZON trial, a pioneering cardiovascular outcomes study, did not… -
Ad hoc release
Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials
Ad hoc announcement pursuant to Art. 53 LR REMODEL-1/-2 trials met their primary endpoint, significantly reducing annualized relapse rate (ARR) vs teriflunomide in people living with… -
Ad hoc release
Novartis verzeichnete im zweiten Quartal Umsatzsteigerungen und baute die Pipeline weiter aus; Prognose für das Geschäftsjahr bekräftigt
Ad-hoc-Mitteilung gemäss Art. 53 KRZweites QuartalDer Nettoumsatz stieg um +1% (kWk1, +3% USD), das operative Kernergebnis1 blieb unverändert (kWk und USD)Das Umsatzwachstum beruhte auf den… -
Ad hoc release
Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed
Ad hoc announcement pursuant to Art. 53 LRSecond quarterNet sales grew +1% (cc1, +3% USD), with core operating income1 flat (cc and USD)Sales growth driven by priority brands including Kisqali (+43%… -
Ad hoc release
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary endpoints of reduction in KHDC1L and creatine kinase levels, with safety profile consistent with previous… -
Ad hoc release
Novartis erzielte im ersten Quartal mit prioritären Marken und Neueinführungen ein starkes Wachstum; Prognose für das Geschäftsjahr 2026 bekräftigt
Ad-hoc-Mitteilung gemäss Art. 53 KR Erstes QuartalDer Nettoumsatz ging um –5% (kWk1, –1% USD) zurück, da Wachstumstreiber durch Einbussen durch Generika in den USA mehr als… -
Ad hoc release
Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed
Ad hoc announcement pursuant to Art. 53 LRFirst quarterNet sales declined -5% (cc1, -1% USD), as growth drivers were more than offset by US generic erosionContinued strong performance from priority… -
Ad hoc release
Novartis erzielte im Jahr 2025 eine Umsatzsteigerung im hohen einstelligen Prozentbereich, eine Kerngewinnmarge von 40% sowie weitere Fortschritte in der Pipeline
Ad-hoc-Mitteilung gemäss Art. 53 KRGeschäftsjahrDer Nettoumsatz wuchs um +8% (kWk1, +8% USD), das operative Kernergebnis1 verbesserte sich um +14% (kWk, +12% USD)Das Umsatzwachstum beruhte auf… -
Ad hoc release
Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025
Ad hoc announcement pursuant to Art. 53 LRFull yearNet sales grew +8% (cc1, +8% USD) with core operating income1 up +14% (cc, +12% USD) Sales growth driven by continued strong performance from…
-
Statement
Europe Is Losing the Pharma Investment Race – But the Comeback Is Within Reach: An open letter from the Chairs of AstraZeneca, Boehringer Ingelheim, Chiesi Group, Ipsen, GSK, Novo, Novartis, Roche, and Sanofi
-
Statement
Novartis withdraws EMA application for adding new indication for Pluvicto®
-
Statement
Bringing breakthroughs to more patients
-
Statement
Vas Narasimhan named to 2025 TIME100 Health list
-
Statement
Europe talks health sovereignty — now it must deliver
-
Statement
Novartis statement on Maximum Fair Price for Entresto
-
Statement
Violence against innocent people runs counter to our work to improve human health
-
Statement
Novartis condemns the terrorist actions against people in Israel and loss of innocent lives
-
Statement
Novartis statement on collaboration and license agreement for tislelizumab with BeiGene, Ltd.
Novartis and BeiGene, Ltd. have mutually agreed to terminate the collaboration and license agreement for tislelizumab, a humanized IgG4 anti-PD-1 monoclonal antibody.
-
Statement
Novartis provides support for Moroccan earthquake victims
-
Statement
GT005 (PPY988): Development Program in Geographic Atrophy
-
Statement
Novartis statement on filing of Inflation Reduction Act lawsuit
-
Story People and Culture
Novartis ranks #19 in TIME and Statista’s World’s Best Companies 2026
Novartis has earned a spot among the world’s top performers, ranking #19 in TIME and Statista’s World’s Best Companies 2026 – a significant rise from #114 last year. The recognition reflects progress across three critical areas: business performance, workplace experience, and sustainability.
-
Story Access to Healthcare
Community health takes a village: Screening in the barber’s chair
Novartis is working with community partners to bring heart disease and cancer screening, information and support closer to where people are.
-
Story People and Culture
Novartis achieves Tier 1 in the 2026 CCLA Corporate Mental Health Benchmark
Novartis has reached the highest performance tier in the CCLA Corporate Mental Health Benchmark, recognizing a comprehensive approach to workplace mental health, wellbeing and employee support.
-
Story People and Culture
The patient who changed the course of my career
Nazem Atassi, Development Unit Head for Neuroscience and Gene Therapies, Global Drug Development.
-
Story Access to Healthcare
Community health takes a village: from Pulpit to Pew
Millions of people around the world continue to face barriers to prevention, diagnosis and treatment for chronic diseases such as heart disease and cancer. To help address these gaps, Novartis is scaling its community health programs from 11 to more than 30 countries by 2030, working alongside local partners to connect more people to care.
-
Story Access to Healthcare
Fortune includes Novartis in 2026 Change The World List for malaria program
For more than three decades, Novartis has been committed to the fight against malaria, one of the world's deadliest diseases. Fortune has now recognized that work by naming our malaria program to its 2026 Change The World list.
-
Story People and Culture
The Day AI Made Me Rethink What Science Could Do
Christian Diehl, Chief Data & Digital Officer, Novartis Biomedical Research
-
Story Discovery
American Chemical Society honors Novartis researchers
Novartis chemists receive “Heroes of Chemistry” honor from the American Chemical Society for work on CML drug discovery.
-
Story Access to Healthcare
25 years of expanding access to cancer care
For a quarter of a century, Novartis and The Max Foundation have worked together to help people living with cancer in low- and middle-income countries access the care they need.
-
Story Discovery
Smarter decisions at scale: How Novartis is using AI to advance R&D
Novartis R&D is harnessing digital technologies to make smart decisions faster, aiming to reduce the time it takes to bring new options to patients
-
Story People and Culture
Small shifts. Big impact. The leadership choices that matter most in the age of AI
There is no shortage of conversation about what AI can do. Every day brings a new headline, a new capability, a new prediction about how work will change.
-
Story Discovery
How Novartis R&D is advancing the next breakthrough innovations
Novartis R&D leaders discuss how Novartis science, technology and strategy are shaping the next decade of innovation
Novartis Financial Results – Q3 2026
Novartis announces the company’s financial results for the third quarter of 2026.
Stories
Our research redefines the way we understand disease and develop medicines. Discover the people and stories that make it possible.
Events
Keep informed about the latest Novartis events. From upcoming congresses and conferences to special forums, explore our event calendar for ongoing opportunities to connect and engage.
